Pomalidomide Capsules 4mg
IMNOLIEVA 4 MG (Pomalidomide Capsules 4 mg) is a prescription anticancer medicine containing Pomalidomide 4 mg, an immunomodulatory agent used primarily in the treatment of Multiple Myeloma, a type of blood cancer that affects plasma cells in the bone marrow. Pomalidomide belongs to a class of medicines known as Immunomodulatory Drugs (IMiDs) and works by helping the immune system fight cancer while also directly inhibiting the growth and survival of malignant cells.
Multiple Myeloma develops when abnormal plasma cells multiply uncontrollably within the bone marrow. These cancerous cells can interfere with the production of healthy blood cells, weaken bones, and affect kidney function. Pomalidomide helps slow disease progression by targeting multiple pathways involved in cancer growth, immune regulation, and blood vessel formation that support tumor development.
IMNOLIEVA 4 MG is commonly prescribed for patients whose disease has returned after previous treatment or has become resistant to other therapies. It is often used in combination with other anticancer medicines and corticosteroids as part of comprehensive treatment strategies recommended by hematologists and oncologists.
Unlike conventional chemotherapy, Pomalidomide has a unique mechanism that combines direct anticancer effects with immune system modulation. This dual action makes it an important treatment option in modern multiple myeloma management.
IMNOLIEVA 4 MG is commonly prescribed for:
Multiple Myeloma
Relapsed Multiple Myeloma
Refractory Multiple Myeloma
Advanced Plasma Cell Disorders
Combination Cancer Therapy Programs
Long-Term Hematology Treatment Plans
Immunomodulatory Cancer Treatment
Specialized Oncology Care
The medicine is widely used in modern hematology and oncology practice and has become an essential component of treatment strategies for patients with relapsed or treatment-resistant multiple myeloma.
Manufactured according to strict pharmaceutical quality standards, IMNOLIEVA 4 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Pomalidomide therapy require regular medical monitoring, including complete blood counts, liver and kidney function tests, and routine clinical evaluations to ensure optimal treatment outcomes and patient safety.
Due to its proven effectiveness and unique immunomodulatory properties, IMNOLIEVA 4 MG remains an important treatment option in advanced multiple myeloma care worldwide.
View Details
Pomalidomide Capsules 2mg
IMNOLIEVA 2 MG (Pomalidomide Capsules 2 mg) is a prescription anticancer medication containing Pomalidomide 2 mg, an advanced immunomodulatory agent used primarily in the treatment of Multiple Myeloma, a cancer that develops in plasma cells within the bone marrow. Pomalidomide belongs to a group of medicines known as Immunomodulatory Drugs (IMiDs), which help strengthen the body's immune response against cancer cells while directly inhibiting tumor growth and survival.
Multiple Myeloma occurs when abnormal plasma cells multiply uncontrollably in the bone marrow. These cancerous cells can interfere with the production of healthy blood cells, weaken bones, increase the risk of infections, and affect kidney function. Pomalidomide helps manage the disease by targeting several pathways involved in cancer cell growth, immune system regulation, and tumor development.
IMNOLIEVA 2 MG is commonly prescribed for patients with relapsed or refractory Multiple Myeloma, particularly when previous treatments have not produced the desired results or when the disease returns after earlier therapy. The medicine is often used in combination with other anticancer medicines and corticosteroids as part of comprehensive treatment regimens developed by hematologists and oncologists.
Unlike traditional chemotherapy, Pomalidomide offers a targeted and immune-based approach to cancer treatment. It helps activate specific immune cells, suppresses cancer cell growth, and reduces the formation of new blood vessels that tumors require for continued growth.
IMNOLIEVA 2 MG is commonly prescribed for:
Multiple Myeloma
Relapsed Multiple Myeloma
Refractory Multiple Myeloma
Plasma Cell Disorders
Advanced Blood Cancer Management
Combination Oncology Treatment Programs
Long-Term Hematology Care
Immunomodulatory Cancer Therapy
The medicine has become an important component of modern blood cancer treatment and is widely used in specialized oncology and hematology centers worldwide.
Manufactured according to strict pharmaceutical quality standards, IMNOLIEVA 2 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Pomalidomide therapy require regular medical supervision, including blood tests, liver function monitoring, kidney assessments, and routine clinical evaluations to ensure optimal treatment outcomes.
Due to its proven clinical effectiveness in managing advanced Multiple Myeloma, IMNOLIEVA 2 MG remains a trusted option in modern cancer care.
View Details
Megestrol Tablets IP 160mg
MEGESLIEVA 160 MG (Megestrol Tablets IP 160 mg) is a prescription medication containing Megestrol Acetate 160 mg, a synthetic progestin widely used in oncology and supportive care. It is commonly prescribed for the management of certain hormone-sensitive cancers and for the treatment of loss of appetite (anorexia), significant weight loss, and cancer-related cachexia in patients requiring nutritional support.
Megestrol Acetate belongs to a class of medicines known as progestational agents. It works by influencing hormone activity within the body and helping regulate processes associated with appetite, metabolism, and cell growth. In oncology, Megestrol may be used as part of treatment strategies for selected hormone-responsive cancers, while in supportive care it is frequently prescribed to stimulate appetite and promote weight gain in patients experiencing unintended weight loss.
Cancer and chronic illnesses can often lead to poor appetite, nutritional deficiencies, and muscle wasting, which may affect overall quality of life and treatment outcomes. MEGESLIEVA 160 MG helps improve appetite, increase food intake, and support weight maintenance, making it an important supportive therapy for many patients undergoing cancer treatment or living with chronic medical conditions.
MEGESLIEVA 160 MG is commonly prescribed for:
Cancer-Related Appetite Loss
Cancer Cachexia (Cancer-Related Weight Loss)
Unexplained Weight Loss
Nutritional Support Therapy
Advanced Cancer Supportive Care
Hormone-Sensitive Breast Cancer (Selected Cases)
Hormone-Sensitive Endometrial Cancer
Long-Term Supportive Oncology Care
Appetite Stimulation Programs
The medicine may be prescribed alone or as part of a broader treatment plan depending on the patient's medical condition and therapeutic goals.
Manufactured according to stringent pharmaceutical quality standards, MEGESLIEVA 160 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Megestrol therapy should undergo regular medical evaluations to monitor treatment response, body weight, nutritional status, and overall health.
Due to its established role in appetite stimulation and supportive oncology care, MEGESLIEVA 160 MG remains an important treatment option in modern clinical practice.
View Details
Gefitinib Tablets IP 250mg
GEFLIEVA 250 MG (Gefitinib Tablets IP 250 mg) is a prescription targeted anticancer medicine containing Gefitinib 250 mg, which is primarily used for the treatment of Epidermal Growth Factor Receptor (EGFR) mutation-positive Non-Small Cell Lung Cancer (NSCLC). Gefitinib belongs to a class of medications known as Tyrosine Kinase Inhibitors (TKIs) that work by blocking specific proteins responsible for the growth and spread of cancer cells.
Non-Small Cell Lung Cancer is the most common type of lung cancer, accounting for the majority of lung cancer cases worldwide. Certain patients with NSCLC have specific EGFR gene mutations that cause uncontrolled cancer cell growth. GEFLIEVA 250 MG is specifically designed to target these mutations and inhibit the signaling pathways that promote tumor development and progression.
Unlike conventional chemotherapy, which affects both healthy and cancerous cells, Gefitinib provides a more precise and targeted approach to cancer treatment. By directly targeting EGFR-positive cancer cells, it helps slow tumor growth while minimizing damage to normal tissues.
GEFLIEVA 250 MG is commonly prescribed for:
EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)
Advanced Lung Cancer
Metastatic Lung Cancer
Locally Advanced NSCLC
Recurrent Lung Cancer
First-Line Targeted Therapy for Eligible Patients
Precision Oncology Treatment Programs
Long-Term Cancer Management
Before starting treatment, healthcare professionals typically perform molecular testing to confirm the presence of EGFR mutations. This helps identify patients who are most likely to benefit from Gefitinib therapy.
Gefitinib has become an important part of modern precision oncology because it specifically targets cancer-driving genetic abnormalities. It is often prescribed as a first-line treatment for eligible patients and may also be used in certain advanced-stage cancer treatment plans.
Manufactured under stringent pharmaceutical quality standards, GEFLIEVA 250 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Gefitinib therapy usually require routine monitoring, including clinical assessments, liver function tests, blood investigations, and regular follow-up appointments to evaluate treatment response and manage potential side effects.
Due to its targeted mechanism and proven clinical benefits, GEFLIEVA 250 MG remains an important treatment option for patients with EGFR-positive lung cancer worldwide.
View Details
Capecitabine Tablets IP 500mg
CAPELIEVA 500 MG (Capecitabine Tablets IP 500 mg) is a prescription anticancer medicine containing Capecitabine 500 mg, an oral chemotherapy medication widely used for the treatment of various types of cancer, including colorectal cancer, breast cancer, gastric cancer, and other advanced solid tumors. Capecitabine belongs to a class of medicines known as antimetabolites, which work by interfering with the growth and multiplication of cancer cells.
Capecitabine is considered a prodrug, meaning it is converted inside the body into 5-Fluorouracil (5-FU), a well-established anticancer agent. This conversion occurs more actively within tumor tissues, helping target cancer cells while reducing exposure to healthy tissues. As a result, CAPELIEVA 500 MG offers the convenience of oral administration while delivering the proven benefits of fluoropyrimidine-based cancer therapy.
Cancer develops when abnormal cells grow uncontrollably and spread to other parts of the body. CAPELIEVA 500 MG helps slow or stop this process by disrupting DNA synthesis in rapidly dividing cancer cells, thereby reducing tumor growth and progression.
The medicine is frequently prescribed as a standalone therapy or in combination with other chemotherapy agents, targeted therapies, or radiation treatment depending on the type and stage of cancer.
CAPELIEVA 500 MG is commonly prescribed for:
Colorectal Cancer
Metastatic Colorectal Cancer
Breast Cancer
Metastatic Breast Cancer
Gastric (Stomach) Cancer
Advanced Gastrointestinal Cancers
Combination Chemotherapy Regimens
Long-Term Oncology Treatment Programs
One of the key advantages of Capecitabine is that it allows patients to receive chemotherapy treatment at home under the supervision of their oncologist, reducing the need for frequent hospital-based infusions.
Manufactured according to strict pharmaceutical quality standards, CAPELIEVA 500 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Capecitabine therapy require regular medical monitoring, including blood tests, liver and kidney function assessments, and routine clinical evaluations to ensure safe and effective treatment.
Due to its proven clinical effectiveness and convenient oral administration, CAPELIEVA 500 MG remains an important component of modern cancer treatment worldwide.
View Details
Abiraterone Acetate Tablets IP 500mg
ABIRALIEVA 500 MG (Abiraterone Acetate Tablets IP 500 mg) is a prescription anticancer medicine containing Abiraterone Acetate 500 mg, a targeted hormonal therapy used primarily for the treatment of prostate cancer. It is commonly prescribed for patients with metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) as part of a comprehensive oncology treatment plan.
Abiraterone Acetate belongs to a class of medicines known as androgen biosynthesis inhibitors. Prostate cancer cells often depend on male hormones called androgens, particularly testosterone, to grow and multiply. ABIRALIEVA 500 MG works by blocking an enzyme called CYP17 (17α-hydroxylase/C17,20-lyase), which plays a crucial role in the production of androgens in the testes, adrenal glands, and tumor tissues.
By significantly reducing androgen levels throughout the body, Abiraterone helps slow the growth and spread of prostate cancer cells. This targeted mechanism has made it one of the most important advances in the treatment of advanced prostate cancer.
Unlike conventional chemotherapy, Abiraterone specifically targets hormone production pathways associated with prostate cancer progression. It is frequently prescribed alongside corticosteroids such as prednisone or prednisolone to help manage certain treatment-related effects and optimize therapeutic outcomes.
ABIRALIEVA 500 MG is commonly prescribed for:
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Advanced Prostate Cancer
Recurrent Prostate Cancer
Hormone-Driven Prostate Tumors
Long-Term Prostate Cancer Management
Combination Hormonal Therapy Programs
Precision Oncology Treatment Plans
The medicine has become a cornerstone of modern prostate cancer treatment due to its ability to improve disease control and support long-term management strategies.
Manufactured under stringent pharmaceutical quality standards, ABIRALIEVA 500 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Abiraterone therapy typically undergo regular monitoring, including liver function tests, blood pressure assessments, potassium level evaluations, and routine clinical examinations to ensure safe and effective treatment.
Due to its proven clinical efficacy and targeted hormonal action, ABIRALIEVA 500 MG remains an important treatment option in advanced prostate cancer care worldwide.
View Details
Abiraterone Acetate Tablets IP 250mg
ABIRALIEVA 250 MG (Abiraterone Acetate Tablets IP 250 mg) is a prescription anticancer medicine containing Abiraterone Acetate 250 mg, a targeted hormonal therapy widely used in the treatment of advanced prostate cancer. It is specifically designed to help manage prostate cancers that depend on male hormones, known as androgens, for growth and survival.
Prostate cancer is one of the most common cancers affecting men worldwide. In many cases, cancer cells continue to grow even after conventional hormone-lowering treatments. ABIRALIEVA 250 MG helps address this challenge by reducing androgen production throughout the body, thereby slowing cancer progression and helping improve treatment outcomes.
Abiraterone Acetate belongs to a class of medicines called Androgen Biosynthesis Inhibitors. It works by blocking the activity of the CYP17 enzyme, which plays a crucial role in the production of testosterone and other androgens in the adrenal glands, testes, and prostate tumor tissues. By significantly reducing androgen levels, the medicine helps limit the growth and spread of prostate cancer cells.
Unlike traditional chemotherapy, which directly attacks rapidly dividing cells, Abiraterone targets hormone production pathways associated with cancer progression. This targeted mechanism has made it an important component of modern prostate cancer treatment strategies.
ABIRALIEVA 250 MG is commonly prescribed for:
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Advanced Prostate Cancer
Recurrent Prostate Cancer
Hormone-Dependent Prostate Cancer
Long-Term Cancer Management
Combination Hormonal Therapy Programs
Precision Oncology Treatment Plans
The medicine is often used in combination with corticosteroids such as prednisone or prednisolone as recommended by healthcare professionals.
Manufactured according to stringent pharmaceutical quality standards, ABIRALIEVA 250 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Abiraterone therapy require regular monitoring, including liver function tests, blood pressure assessments, potassium level evaluations, and routine clinical examinations to ensure safe and effective treatment.
Due to its proven efficacy and targeted hormonal action, ABIRALIEVA 250 MG has become a trusted treatment option for advanced prostate cancer worldwide.
View Details
Palbociclib Capsules 125mg
PALBOLIEVA 125 MG (Palbociclib Capsules 125 mg) is a prescription targeted anticancer medicine containing Palbociclib 125 mg, an advanced CDK4/6 (Cyclin-Dependent Kinase 4 and 6) inhibitor used primarily for the treatment of Hormone Receptor (HR)-Positive, HER2-Negative Breast Cancer. It is commonly prescribed as part of combination therapy with hormonal treatments to help slow cancer growth and improve treatment outcomes.
Breast cancer is one of the most common cancers affecting women worldwide. Certain breast cancers depend on hormones such as estrogen and progesterone for growth. In these cancers, abnormal cell cycle activity can cause uncontrolled tumor growth and disease progression. PALBOLIEVA 125 MG works by targeting proteins known as CDK4 and CDK6, which play a critical role in cell division and cancer cell proliferation.
By blocking these proteins, Palbociclib helps stop cancer cells from progressing through the cell cycle, thereby slowing tumor growth and delaying disease progression. This targeted mechanism has transformed the treatment landscape for HR-positive, HER2-negative advanced breast cancer and has become a standard component of modern oncology care.
Unlike conventional chemotherapy, Palbociclib specifically targets cancer growth pathways while working alongside hormone therapies such as aromatase inhibitors or fulvestrant. This precision-based approach allows for more effective disease control while helping maintain quality of life.
PALBOLIEVA 125 MG is commonly prescribed for:
HR-Positive, HER2-Negative Advanced Breast Cancer
Metastatic Breast Cancer
Locally Advanced Breast Cancer
Recurrent Breast Cancer
Hormone Receptor-Positive Breast Cancer
Combination Endocrine Therapy Programs
Targeted Oncology Treatment Plans
Long-Term Breast Cancer Management
The medicine is typically prescribed after careful evaluation by an oncologist and may be used in different stages of advanced breast cancer treatment depending on the patient's medical condition and treatment history.
Manufactured under stringent pharmaceutical quality standards, PALBOLIEVA 125 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Palbociclib therapy require regular monitoring, including complete blood counts, liver function tests, infection assessments, and routine clinical evaluations to ensure safe and effective treatment.
Due to its proven efficacy and targeted mechanism of action, PALBOLIEVA 125 MG has become an important treatment option in modern breast cancer management worldwide.
View Details
Palbociclib Capsules 100 mg
PALBOLIEVA 100 MG (Palbociclib Capsules 100 mg) is a prescription targeted anticancer medicine containing Palbociclib 100 mg, a highly effective CDK4/6 (Cyclin-Dependent Kinase 4 and 6) inhibitor used in the treatment of Hormone Receptor (HR)-Positive, HER2-Negative Breast Cancer. It is commonly prescribed in combination with hormone therapies to help slow cancer progression, control tumor growth, and improve patient outcomes.
Breast cancer remains one of the most frequently diagnosed cancers worldwide. Many breast cancer cells rely on hormones such as estrogen for growth and survival. In HR-positive breast cancer, abnormal activation of cellular pathways can cause uncontrolled cell division and tumor progression. PALBOLIEVA 100 MG is specifically designed to target these pathways by blocking CDK4 and CDK6 proteins, which are essential for cancer cell multiplication.
By preventing cancer cells from progressing through critical stages of the cell cycle, Palbociclib helps reduce tumor growth and delay disease progression. This targeted mechanism has significantly improved treatment strategies for patients with advanced and metastatic hormone receptor-positive breast cancer.
Unlike traditional chemotherapy, which affects rapidly dividing healthy and cancerous cells alike, Palbociclib offers a more precise approach by targeting specific proteins involved in cancer cell proliferation. This allows it to work effectively alongside endocrine therapies such as aromatase inhibitors and fulvestrant.
PALBOLIEVA 100 MG is commonly prescribed for:
HR-Positive, HER2-Negative Advanced Breast Cancer
Metastatic Breast Cancer
Locally Advanced Breast Cancer
Recurrent Breast Cancer
Hormone Receptor-Positive Breast Cancer
Combination Endocrine Therapy Programs
Targeted Oncology Treatment Plans
Long-Term Breast Cancer Management
The medicine is often used as part of personalized treatment strategies developed by oncologists based on the patient’s cancer stage, medical history, and treatment goals.
Manufactured under stringent pharmaceutical quality standards, PALBOLIEVA 100 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Palbociclib therapy require regular monitoring, including complete blood counts, liver function assessments, infection evaluations, and routine clinical examinations to ensure safe and effective treatment.
Due to its proven efficacy and targeted mechanism of action, PALBOLIEVA 100 MG has become an important treatment option in modern breast cancer care worldwide.
View Details
Enzalutamide Capsules 40mg
ENZALIEVA 40 MG (Enzalutamide Capsules 40 mg) is a prescription anticancer medicine containing Enzalutamide 40 mg, a next-generation androgen receptor inhibitor used for the treatment of advanced prostate cancer. It is specifically designed to help slow the growth and spread of prostate cancer cells by blocking the effects of male hormones, known as androgens, that fuel cancer progression.
Prostate cancer is one of the most commonly diagnosed cancers in men worldwide. Many prostate cancer cells depend on testosterone and other androgens for survival and growth. Even after treatments that lower testosterone levels, cancer cells may continue to grow by activating androgen receptors. ENZALIEVA 40 MG helps overcome this challenge by directly blocking androgen receptor signaling, thereby reducing the ability of cancer cells to multiply and spread.
Enzalutamide belongs to a class of medicines known as Androgen Receptor Inhibitors. Unlike conventional hormone therapies that primarily reduce testosterone production, Enzalutamide works by preventing androgen receptors from receiving hormonal signals. This dual approach helps provide more effective disease control in advanced stages of prostate cancer.
ENZALIEVA 40 MG is commonly prescribed for:
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Advanced Prostate Cancer
Recurrent Prostate Cancer
Long-Term Prostate Cancer Management
Hormone-Driven Prostate Tumors
Precision Oncology Treatment Programs
The medicine may be used as part of a comprehensive cancer treatment plan developed by an oncologist based on the patient's medical condition, disease stage, and treatment history.
Manufactured according to stringent pharmaceutical quality standards, ENZALIEVA 40 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Enzalutamide therapy typically require regular monitoring, including blood pressure assessments, liver function evaluations, neurological monitoring, and routine clinical follow-up to ensure safe and effective treatment.
Due to its targeted mechanism of action and proven clinical benefits, ENZALIEVA 40 MG has become an important treatment option in modern prostate cancer care worldwide.
View Details
Enzalutamide Capsules 40mg
ENZALIEVA 40 MG (Enzalutamide Capsules 40 mg) is a prescription medication containing Enzalutamide 40 mg, a next-generation androgen receptor inhibitor used for the treatment of advanced prostate cancer. It is specifically developed to help control the growth and spread of prostate cancer cells by blocking the effects of male hormones (androgens) that play a crucial role in cancer progression.
Prostate cancer is one of the most commonly diagnosed cancers among men worldwide. While many prostate cancers initially respond to hormone-lowering therapies, some cancers eventually continue to grow despite reduced testosterone levels. ENZALIEVA 40 MG helps address this challenge by directly targeting androgen receptor signaling pathways that cancer cells rely on for survival and multiplication.
Enzalutamide works differently from traditional hormone therapies. Instead of only reducing hormone production, it blocks the androgen receptor at multiple stages, preventing cancer cells from receiving and using hormonal signals. This advanced mechanism helps slow tumor growth, delay disease progression, and support long-term disease management.
ENZALIEVA 40 MG is widely prescribed for patients with:
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Advanced Prostate Cancer
Recurrent Prostate Cancer
Hormone-Driven Prostate Tumors
Long-Term Prostate Cancer Management
Precision Oncology Treatment Programs
The medicine has become an important part of modern prostate cancer treatment because of its proven ability to improve progression-free survival and help maintain quality of life in eligible patients.
Unlike conventional chemotherapy, ENZALIEVA 40 MG specifically targets pathways involved in prostate cancer growth, making it a highly effective option for selected patients. It is often prescribed as part of a comprehensive oncology treatment plan under the supervision of experienced healthcare professionals.
Manufactured according to stringent pharmaceutical quality standards, ENZALIEVA 40 MG is designed to deliver consistent therapeutic performance, safety, and reliability.
Regular follow-up appointments, laboratory testing, and clinical evaluations are important during treatment to monitor effectiveness and manage any potential side effects.
View Details
Olaparib Tablets 150mg
PARIBLIEVA 150 MG (Olaparib Tablets 150 mg) is a prescription targeted anticancer medicine containing Olaparib 150 mg, a highly advanced PARP (Poly ADP-Ribose Polymerase) inhibitor used in the treatment of several types of cancer associated with specific genetic mutations, particularly BRCA1 and BRCA2 mutations. Olaparib is widely used in modern precision oncology to help slow cancer growth, delay disease progression, and improve treatment outcomes in eligible patients.
Cancer cells with BRCA gene mutations often have difficulty repairing damaged DNA. PARIBLIEVA 150 MG works by blocking PARP enzymes, which cancer cells use to repair their DNA. When both repair mechanisms are disrupted, cancer cells are unable to survive and eventually die. This targeted approach allows Olaparib to selectively attack cancer cells while minimizing damage to healthy tissues.
PARIBLIEVA 150 MG has become an important treatment option in personalized cancer care and is commonly prescribed for patients whose tumors carry specific genetic abnormalities. Genetic testing is often performed before treatment to determine whether a patient is likely to benefit from Olaparib therapy.
Unlike conventional chemotherapy, which affects rapidly dividing cells throughout the body, Olaparib specifically targets cancer cells with defective DNA repair pathways. This precision-based mechanism has transformed the treatment landscape for several difficult-to-treat cancers.
PARIBLIEVA 150 MG is commonly prescribed for:
BRCA-Mutated Ovarian Cancer
Advanced Ovarian Cancer
Recurrent Ovarian Cancer
BRCA-Mutated Breast Cancer
HER2-Negative Breast Cancer with BRCA Mutation
Metastatic Breast Cancer
Pancreatic Cancer with BRCA Mutation
Metastatic Pancreatic Cancer
Prostate Cancer with Homologous Recombination Repair (HRR) Gene Mutations
Precision Oncology Treatment Programs
The medicine may be used as maintenance therapy after successful cancer treatment or as part of long-term disease management plans, depending on the patient's condition and oncologist’s recommendations.
Manufactured according to stringent pharmaceutical quality standards, PARIBLIEVA 150 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Olaparib therapy require routine monitoring, including blood tests, kidney and liver function assessments, and regular clinical evaluations to ensure safe and effective treatment.
Due to its targeted mechanism and proven clinical benefits, PARIBLIEVA 150 MG has become a valuable treatment option in modern cancer care worldwide.
View Details
